TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01886170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase II of the Study: Information regarding Current Diabetes Control
Description: Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase II of the Study: Information regarding Current Diabetes Control
Description: Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
Study: NCT03456726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be provided as a 200 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be provided as a 200 mg oral tablet.
Study: NCT03952936

Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular Rehabilitation
Description: standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
Study: NCT03963999

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Elastography
Description: Ultrasound shear wave elastography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Ultrasound (CEUS)
Description: Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
Study: NCT03501199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet-rich fibrin placement
Description: filling the buccal gap with platelet-rich fibrin after immediate dental implant placement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xenogenic graft placement
Description: filling the buccal gap with xenogenic graft after immediate dental implant placement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no extra material
Description: filling the buccal gap with no material after immediate dental implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth extraction
Description: extraction of tooth which is unrestorable

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth extraction
Description: extraction of tooth which is unrestorable

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth extraction
Description: extraction of tooth which is unrestorable

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: putting dental implant into a socket which has been prepared with compatible drills

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: putting dental implant into a socket which has been prepared with compatible drills

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: putting dental implant into a socket which has been prepared with compatible drills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collagen membran placement
Description: placing collagen membran on extraction socket after dental implant placement to cover all

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collagen membran placement
Description: placing collagen membran on extraction socket after dental implant placement to cover all

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collagen membran placement
Description: placing collagen membran on extraction socket after dental implant placement to cover all

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: raising flap
Description: raising the buccal flap with two vertical incision to cover extraction socket for primary closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: raising flap
Description: raising the buccal flap with two vertical incision to cover extraction socket for primary closure
Study: NCT02124642

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid, 400 mcg/day
Description: The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 800 mcg/day
Description: The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
Study: NCT03874676

Intervention type: OTHER
Intervention: PEACE Rounds
Description: PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
Study: NCT00817089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of naltrexone prior to challenge session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of naltrexone prior to challenge session
Study: NCT03073889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp Nerve Block
Description: A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalp infiltration
Description: Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT01663493

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNB

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNB
Study: NCT00561223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost Inhalation
Description: inhale 2.5 mg, repeat times one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: inhaled 2.5 mg, repeat times one
Study: NCT03535818

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
Study: NCT02176317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
Study: NCT03741309

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% fluorocalcium phosphosilicate dentifrice
Description: dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
Study: NCT03501199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: raising flap
Description: raising the buccal flap with two vertical incision to cover extraction socket for primary closure
Study: NCT04507529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-mentoring
Description: Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
Study: NCT04093167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Per current Product Monograph/U.S. Drug Label and/or local guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Per current Product Monograph/U.S. Drug Label and/or local guidelines.
Study: NCT01317420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Intravenous infusion once every three weeks
Study: NCT01111630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recomon (Epoetin Beta)
Description: administer once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recomon (Epoetin Beta)
Description: administer three times weekly
Study: NCT03329586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity training
Description: 6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
Study: NCT03779113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Oral HMPL-523
Study: NCT01465893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: vitamin D ,50000 unit /week

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vitamin D withheld
Description: do not receive anything
Study: NCT03748498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser
Description: Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
Study: NCT01283269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System
Description: Training in use of a memory notebook system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Training
Description: Computer brain fitness training
Study: NCT03958903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala recording and stimulation using Neuropace RNS
Description: Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral tasks
Description: Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
Study: NCT00283504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANTI-IGE THERAPY (XOLAIR)
Description: Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
Study: NCT02328326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-IMPACT
Description: Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACT
Description: participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
Study: NCT02958436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02556021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg
Description: CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Description: CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablet, once daily, oral administration for up to 4 weeks
Study: NCT00737841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Description: 1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
Study: NCT03466580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Carer Support Needs Assessment Tool (CSNAT) intervention
Description: The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
Study: NCT03727191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (education, guidelines, recommendations)
Description: Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group (education, guidelines, 2 pckts diet, recommendations)
Description: Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
Study: NCT02352064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (18-FDG)
Description: Every patient will have a PET
Study: NCT00986999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
Study: NCT01153646

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Description: Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
Study: NCT03852953

Intervention type: OTHER
Intervention: Under- or overdiagnosed cancer
Description: Diagnosed with a cancer that was visible on prior mammograms
Study: NCT04287374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component Well-being Intervention
Description: The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Study Skills
Description: Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
Study: NCT03675386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional Group
Description: The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
Study: NCT03741309

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Calcium sodium phosphosilicate
Description: Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dentrifice
Description: placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
Study: NCT02542748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: norepinephrine injection

Intervention type: DRUG
Group type: OTHER
Intervention: Ephedrine
Description: Ephedrine injection
Study: NCT04367922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotion Skills Course
Description: The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
Study: NCT02197754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet
Description: Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives.
Study: NCT03365219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis O-Ring Wound Retractor
Description: A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Surgical Retractors
Description: Routine hand-held metal retractors as needed by the surgical team
Study: NCT01273922

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NDV-3 investigational vaccine
Description: Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NDV-3 investigational vaccine
Description: Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
Study: NCT01523522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myoblast injection
Description: Autologous myoblast injection in the anal sphincter

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline solution injection
Description: saline solution injection in anal sphincter
Study: NCT01077349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high volume hemofiltration
Description: (80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis \>1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being \<35 ml/kg/h (or a maximum of 3500 ml/h).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: extra-renal replacement therapy (CVVHDF mode, total effluent \<35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~* Serum creatinine \> 350 micromol/L or increase x3.0 from pre-operative value OR~* Diuresis \< 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~* Or serum urea \> 36 mmol/l OR~* Or life threatening hyperkalemia
Study: NCT03338049

Intervention type: DEVICE
Group type: OTHER
Intervention: Veran System
Description: Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
Study: NCT01493726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Low dose
Description: IM injection, given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Med dose
Description: IM injection, given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, High dose
Description: IM injection, given monthly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed matched placebo IM injection, given monthly